Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of nalmefene in alcohol dependence (339-14-002)
jRCT2080222754Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of nalmefene in alcohol dependence (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Long-term maintenance of reduced alcohol consumption and Long-term safety and tolerability of nalmefene. Started Feb 2015; status: completed.
02
Drugs
nalmefene
03
Conditions
alcohol dependence
Beyond the preview
Go deeper on jRCT2080222754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222754.